285 completed, 109 recruiting, 95 unknown, 89 active not recruiting. 678 Phase 3, 66 Phase 2.
By phase and status
Phase Trials Status Phase 3 678 Completed 285 , Recruiting 109 , Unknown 95 , Active not recruiting 89 , Terminated 61 , Not yet recruiting 21 , Withdrawn 14 , Suspended 4 Phase 2 66 Completed 15 , Recruiting 13 , Unknown 13 , Terminated 10 , Active not recruiting 9 , Not yet recruiting 3 , Withdrawn 2 , Suspended 1
Follow Paclitaxel: new trials by email Literature Review of Paclitaxel trials Research Report on Paclitaxel
Trials (filtered) newest first · largest first
All 678 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
Circulating Tumor DNA MRD-Guided Adjuvant Therapy for Curatively Resected Locally Advanced Esophageal Squamous Cell Carcinoma Tislelizumab - Esophageal Cancer Phase 3 Not yet recruiting 172 2026-12-31 2026-10-29 Two Part (Phase1b/ Phase3) Trial of Subcutaneous Dostarlimab Plus Carboplatin-Paclitaxel in Participants With Primary Advanced or Recurrent Endometrial Cancer Dostarlimab, Carboplatin and paclitaxel - Endometrial Carcinoma, Neoplasms, Endometrial Phase 3 Not yet recruiting 378 2026-11-12 2026-10-19 HB0025-C-0301: A Study to Investigate HB0025 Combined With Chemotherapy as First-Line Treatment for Advanced or Recurrent MMR-proficient Endometrial Cancer HB0025 Injection, Paclitaxel injection, Carboplatin injection - First-line pMMR Endometrial Cancer Phase 3 Recruiting 333 2026-10-20 2026-10-29 FH-006 Versus Investigator's Choice of Chemotherapy in Patients With Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma Who Have Failed Prior PD-1/PD-L1 Inhibitor Combined With Platinum-Based Chemotherapy. FH-006, Paclitaxel, Docetaxel, Irinotecan - Locally Advanced, Recurrent or Metastatic ESCC Patients Who Have Failed Prior PD-1/PD-L1 Inhibitors Combined With Platinum-based Chemotherapy Phase 3 Recruiting 480 2026-10-13 2026-10-27 A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05) R-DXd, Bevacizumab, Carboplatin - Ovarian Cancer, Peritoneal Cancer Phase 3 Recruiting 646 2026-10-07 2026-10-30 A Study to Assess Intravenous ABBV-1480 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First Line Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer in Adult Participants ABBV-1480, Pembrolizumab, Carboplatin - Non-Small Cell Lung Cancer Phase 3 Recruiting 940 2026-09-22 2026-10-20 A Study to Investigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Participants With Platinum-sensitive Ovarian Cancer (BEHOLD-Ovarian02) Mocertatug rezetecan (Mo-Rez), Carboplatin, Paclitaxel - Ovarian Neoplasms Phase 3 Recruiting 690 2026-09-08 2026-10-01 Paclitaxel, Ramucirumab and Tislelizumab Switch Maintenance in Advanced HER2-negative and PD-L1 TAP Score of 5 or More Advanced Gastroesophageal Adenocarcinoma FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin), CAPOX (oxaliplatin/capecitabine), CDDP, 5 Fu - Gastroesophageal Adenocarcinoma Phase 3 Not yet recruiting 244 2026-09-01 2026-08-18 Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma Pegylated liposomal doxorubicin, Paclitaxel - Kaposi Sarcoma, HIV-1-infection Phase 3 Not yet recruiting 130 2026-09-01 2026-01-23 Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer Rina-S, Bevacizumab, Carboplatin - Platinum-Sensitive Ovarian Cancer, Ovarian Cancer Phase 3 Recruiting 688 2026-08-28 2026-10-07 A Study Comparing BL-B01D1 in Combination With PD-1/VEGF Bispecific Antibody Versus Chemotherapy in Combination With PD-1/VEGF Bispecific Antibody in First-line Patients With Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer(PANKU-Lung05) BL-B01D1, PD-1/VEGF bispecific antibody, Paclitaxel - Squamous Non-small-cell Lung Cancer Phase 2 / Phase 3 Not yet recruiting 200 2026-08-01 2026-08-26 A Study of HS-20093 in Patients With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) HS-20093 for Injection, Irinotecan; Paclitaxel; Docetaxel - Esophageal Squamous Cell Carcinoma (ESCC) Phase 3 Not yet recruiting 494 2026-07-31 2026-06-02 Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Advanced Head and Neck Cancer Who Cannot Receive Cisplatin Biospecimen Collection, Carboplatin, Cetuximab - Locally Advanced Hypopharyngeal Squamous Cell Carcinoma, Locally Advanced Laryngeal Squamous Cell Carcinoma Phase 3 Recruiting 454 2026-07-31 2026-10-27 A Study of SYS6043 in Platinum-Resistant, Advanced Ovarian, Primary Peritoneal, or Fallopian Tube Cancers SYS6043, Liposomal doxorubicin, paclitaxel, or topotecan - Platinum-resistant Ovarian Cancer, Platinum-resistant Primary Peritoneal Cancer Phase 3 Recruiting 460 2026-07-15 2026-09-23 A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03) BL-B01D1, Albumin-Bound Paclitaxel, Paclitaxel - Breast Cancer Phase 3 Recruiting 446 2026-07-06 2026-07-23 A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer BL-M07D1, Liposomal Doxorubicin, Paclitaxel - Epithelial Ovarian Cancer, Fallopian Tube Cancer Phase 3 Not yet recruiting 404 2026-07-01 2026-06-29 An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China Rina-S, Paclitaxel, Topotecan - Platinum-resistant Ovarian Cancer Phase 3 Recruiting 82 2026-06-26 2026-11-03 A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC) SYS6010, Enlonstobart, Tislelizumab - Non-small Cell Lung Cancer Phase 3 Not yet recruiting 570 2026-06-25 2026-06-26 A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01) Mocertatug rezetecan, Paclitaxel, Pegylated liposomal doxorubicin (PLD) - Ovarian Neoplasms Phase 3 Recruiting 450 2026-06-18 2026-10-15 A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02) BL-B01D1, Tislelizumab, 5-Fluorouracil - Esophageal Squamous Cell Carcinoma Phase 2 / Phase 3 Recruiting 90 2026-06-09 2026-07-16
Showing 20 of 678. Sign in to see all of them.
Conditions studied Breast Neoplasms (140) · Carcinoma, Non-Small-Cell Lung (139) · Ovarian Neoplasms (87) · Fallopian Tube Neoplasms (51) · Lung Neoplasms (47) · Carcinoma, Ovarian Epithelial (33) · Endometrial Neoplasms (29) · Uterine Cervical Neoplasms (29) · Parkinson Disease 4, Autosomal Dominant Lewy Body (27) · Triple Negative Breast Neoplasms (25) · Esophageal Neoplasms (22) · Neoplasm Metastasis (22) · Stomach Neoplasms (21) · Neoplasms (20) · Esophageal Squamous Cell Carcinoma (18)
Sponsors Merck Sharp & Dohme LLC (44) · National Cancer Institute (NCI) (39) · Hoffmann-La Roche (31) · AstraZeneca (18) · Fudan University (15) · Gynecologic Oncology Group (14) · Bristol-Myers Squibb (13) · Eli Lilly and Company (11) · Alliance for Clinical Trials in Oncology (10) · Jiangsu HengRui Medicine Co., Ltd. (9) · Novartis Pharmaceuticals (9) · Radiation Therapy Oncology Group (9) · SWOG Cancer Research Network (9) · Pfizer (8) · Sichuan Baili Pharmaceutical Co., Ltd. (8)
Countries United States (316) · China (242) · Italy (172) · Spain (172) · Canada (171) · Germany (170) · South Korea (156) · France (155) · United Kingdom (149) · Japan (137) · Poland (124) · Belgium (122) · Australia (119) · Taiwan (116) · Brazil (110)
Top investigators Edith A. Perez, MD (4) · Norman Wolmark, MD (4) · Francesco Perrone, M.D., Ph.D. (3)
Results publications PMID 37185961 , PMID 34037241 , PMID 38431043 , PMID 40966692 , PMID 30633128 , PMID 16236738 , PMID 21941283 , PMID 22547591 , PMID 25332249 , PMID 26101239 , PMID 26454620 , PMID 29562804 , PMID 30808774 , PMID 31395089 , PMID 31622131 , PMID 32450725 , PMID 33231285 , PMID 34252375 , PMID 35073727 , PMID 35101941 , PMID 35511917 , PMID 35610260 , PMID 37139963 , PMID 37158938 , PMID 37411031 , PMID 37465924 , PMID 37499870 , PMID 38383458 , PMID 38468440 , PMID 38642841 , PMID 38913933 , PMID 39191270 , PMID 39369790 , PMID 40207789 , PMID 40341124 , PMID 40373876 , PMID 41332393 , PMID 42167105 , PMID 42579028 , PMID 10481771 , PMID 11917283 , PMID 12048273 , PMID 12636887 , PMID 12668651 , PMID 12826431 , PMID 12829663 , PMID 14581415 , PMID 14656276 , PMID 14673047 , PMID 15073851
NIH funding 2023 (31) , U10CA180868 (30) , U10CA027469 (16) , 2014 (15) , 2025 (12) , U10CA031946 (12) , 2016 (11) , 2018 (11) , 2015 (9) , 2019 (9) , 2017 (8) , U10CA180820 (8) , U10CA032102 (7) , U10CA180821 (6) , 2005 (5)